◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SUPN

Supernus Pharmaceuticals Inc (SUPN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-08-30

Supernus Pharmaceuticals Inc (SUPN) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Rockville, United States with about 778 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SUPN reported $719M in revenue and ($39M) in net income.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Interactive charts & full statements → Open the SUPN valuation workbench →

SUPN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Revenue	$830M	$719M	$662M	$608M	$667M	$580M	$520M	$393M	$409M	$302M	$215M	$144M	$122M	$12M	$1M	$1M	$0M	$38M	$9M	$4M
Gross Profit	$731M	$644M	$584M	$524M	$580M	$505M	$468M	$376M	$394M	$287M	$203M	$136M	$116M	$11M	$1M	$1M	$14M	$47M	$9M	$4M
Gross Margin %	88.1%	89.6%	88.2%	86.2%	86.9%	87.1%	89.9%	95.8%	96.2%	95.0%	94.4%	94.2%	95.3%	90.8%	100.0%	100.0%	12745.3%	122.6%	100.0%	100.0%
Operating Income (EBIT)	($112M)	($37M)	$82M	($5M)	$46M	$86M	$174M	$149M	$144M	$100M	$54M	$18M	$24M	($62M)	($42M)	($38M)	($40M)	$4M	($26M)	($19M)
Operating Margin %	-13.5%	-5.1%	12.3%	-0.9%	6.9%	14.8%	33.4%	37.8%	35.3%	32.9%	25.2%	12.2%	19.9%	-515.2%	-2849.3%	-4701.4%	-37851.9%	10.6%	-290.9%	-449.9%
Net Income	($110M)	($39M)	$74M	$1M	$61M	$53M	$127M	$113M	$111M	$57M	$91M	$14M	$20M	($92M)	($46M)	$56M	($38M)	$0M	($33M)	($17M)
Net Margin %	-13.2%	-5.4%	11.2%	0.2%	9.1%	9.2%	24.4%	28.8%	27.1%	18.9%	42.4%	9.7%	16.3%	-767.7%	-3127.3%	6974.2%	-36285.8%	1.2%	-376.7%	-408.0%
EBITDA	($16M)	$43M	$178M	$90M	$153M	$129M	$211M	$180M	$152M	$108M	$57M	$22M	($4M)	($84M)	($42M)	($37M)	($38M)	$5M	($24M)	($16M)
Earnings Per Share (EPS)	$-1.91	$-0.68	$1.32	$0.02	$0.98	$0.98	$2.36	$2.10	$2.05	$1.07	$1.76	$0.27	$0.39	$-2.90	$-2.65	$4.04	$-2.78	$0.03	$-2.42	$-1.25
Shares Outstanding (M)	58M	56M	56M	56M	62M	54M	54M	54M	54M	53M	52M	51M	51M	32M	17M	14M	14M	14M	14M	14M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$219M	$208M	$212M	$192M	$165M	$150M	$174M	$176M
Gross Profit	$185M	$184M	$189M	$173M	$149M	$134M	$148M	$158M
Gross Margin %	84.6%	88.7%	89.1%	90.1%	89.8%	89.5%	85.0%	90.0%
Operating Income (EBIT)	($58M)	($7M)	$14M	($60M)	$12M	($10M)	$21M	$41M
Operating Margin %	-26.5%	-3.6%	6.5%	-31.4%	7.3%	-6.9%	12.3%	23.2%
Net Income	($58M)	($2M)	($4M)	($45M)	$22M	($12M)	$15M	$38M
Net Margin %	-26.7%	-1.1%	-1.9%	-23.5%	13.6%	-7.9%	8.8%	21.9%
EBITDA	($30M)	$20M	$27M	($33M)	$38M	$18M	$45M	$65M
Earnings Per Share (EPS)	$-1.01	$-0.04	$-0.07	$-0.80	$0.40	$-0.21	$0.27	$0.69
Shares Outstanding (M)	58M	58M	57M	57M	57M	56M	56M	56M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Cash from Operations (CFO)	$20M	$47M	$172M	$111M	$117M	$127M	$138M	$143M	$129M	$115M	$67M	$32M	$8M	($58M)	($47M)	($36M)	($33M)	$3M	($30M)	($14M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$1M	$0M	$2M	$3M	$3M	$1M	$2M	$2M	$2M	$1M	$2M	$1M	$1M	$0M	$1M	$0M	$1M
Free Cash Flow (FCF)	$19M	$46M	$171M	$111M	$116M	$125M	$135M	$140M	$128M	$113M	$65M	$30M	$7M	($60M)	($48M)	($37M)	($33M)	$2M	($30M)	($15M)
FCF Margin %	2.3%	6.4%	25.9%	18.2%	17.4%	21.6%	25.9%	35.8%	31.3%	37.3%	30.3%	20.8%	5.9%	-501.7%	-3240.0%	-4591.5%	-30979.2%	5.1%	-335.1%	-355.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($5M)	$67M	$20M	($62M)	$59M	$31M	$44M	$54M
Capital Expenditures (CapEx)	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($5M)	$67M	$19M	($62M)	$58M	$30M	$44M	$53M
FCF Margin %	-2.5%	32.0%	9.2%	-32.2%	35.1%	20.2%	25.4%	30.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SUPN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$1.4B	$1.5B	$1.4B	$1.3B	$1.7B	$1.7B	$1.5B	$1.2B	$978M	$424M	$310M	$189M	$138M	$111M	$94M	$54M	$47M	$80M	$77M
Cash & Cash Equivalents	$180M	$128M	$69M	$75M	$93M	$203M	$289M	$181M	$192M	$100M	$90M	$62M	$74M	$82M	$89M	$49M	$24M	$31M	$53M
Total Liabilities	$397M	$391M	$332M	$356M	$816M	$873M	$759M	$565M	$525M	$157M	$118M	$70M	$66M	$78M	$36M	$44M	$91M	$86M	$84M
Total Debt (Short + Long-Term)	$11M	$11M	$7M	$8M	$409M	$386M	$366M	$348M	$332M	$4M	$74M	$8M	$53M	$53M	$23M	$31M	$0M	$0M	$0M
Total Shareholders' Equity	$1.0B	$1.1B	$1.0B	$922M	$886M	$816M	$745M	$595M	$453M	$267M	$192M	$119M	$71M	$33M	$58M	$9M	($44M)	($6M)	($7M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SUPN viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

LQDA · Liquidia Technologies Inc — $6 billion
AMLX · Amylyx Pharmaceuticals Inc — $4 billion
INDV · Indivior PLC Ordinary Shares — $4 billion
RGC · Regencell Bioscience Holdings Ltd — $3 billion
HCM · HUTCHMED DRC — $2 billion
BCRX · BioCryst Pharmaceuticals Inc — $2 billion
TRLV · Trulieve Cannabis Corp. — $2 billion
PBH · Prestige Brand Holdings Inc — $2 billion

← SUPL All “S” companies SUPP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.